Search Cartalax before and after and you get testimonials and stock photos. The published record is about 4 preclinical papers since 2015, all from one research group, and not one of them measured a human being.
The short answer. No published human study of Cartalax exists, so there is no measured before and after.
- The record is about 4 preclinical papers since 2015, all from one research group.
- The cell work used nanomolar concentrations and read gene expression, not patient outcomes.
- Most benefit claims borrow Epitalon data, which is a different, four-amino-acid peptide.
Cartalax is the AED tripeptide, about 333 Da. No human trial has ever measured it. PubMed holds roughly 4 papers since 2015. All of them are preclinical. All come from the same lab group. Zero Western RCTs have tested it in people.
What was actually measured in Cartalax research
The whole Cartalax record is cells and tissue, not patients. There is no before photo and no after photo in any paper.
The work people point to is gene expression in cell culture. Ashapkin and colleagues, writing in Molecular Biology Reports in 2020, grew human mesenchymal stem cells until the cultures aged. They then added short Khavinson-family peptides at nanomolar concentrations and read out what the genes did.
Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.
Ashapkin et al., Molecular Biology Reports, 2020 (paper title)That is the level of the evidence. A shift in a small set of genes, around 5 genes in the reported panels, inside a dish. It is a real experiment. It is not a result in a person.
- No control arm in humans. There is no human arm at all.
- No validated score. No WOMAC, no KOOS, no pain scale, because no patients were enrolled.
- No imaging. No X-ray, no MRI, no cartilage thickness measurement.
- One source. The papers trace back to a single group in Saint Petersburg.
We set out the full publication count on the Cartalax benefits page.
Most of the "evidence" belongs to a different peptide
This is the part that gets lost. Many Cartalax claims are built on Epitalon data.
Epitalon is the AEDG tetrapeptide. Cartalax is the AED tripeptide, about 333 Da. They share three letters. They are not the same molecule, and a result for one is not a result for the other.
The 2025 review in the International Journal of Molecular Sciences that sellers quote is an Epitalon review, start to finish.
Overview of Epitalon — highly bioactive pineal tetrapeptide with promising properties.
Araj et al., International Journal of Molecular Sciences, 2025 (paper title)The word in that title is "promising," not proven, and the subject is a tetrapeptide. The 2020 Molecules paper by Khavinson and colleagues on neurogenesis is also AEDG. Borrowing either one for a Cartalax photo caption is swapping the compound mid-sentence.
If a before-and-after claim cites Epitalon work, it is not evidence about Cartalax. It is evidence about a different peptide that also has no Western RCT.
The Cartalax complete guide tracks which paper belongs to which sequence.
What a real joint before and after would have to show
Cartalax is sold as the joint peptide. Joint disease is one of the most studied endpoints in medicine, so the bar is clear and public.
The GBD 2021 Osteoarthritis Collaborators put the scale plainly in The Lancet Rheumatology.
In 2020, 595 million people worldwide were living with osteoarthritis.
GBD 2021 Osteoarthritis Collaborators, The Lancet Rheumatology, 2023With 595 million people affected, trials in this space are large, blinded and scored with validated instruments. Here is what exists for Cartalax against that standard.
| Evidence type | Cartalax record |
|---|---|
| Randomized controlled trial | Zero |
| Any human study | None published in PubMed |
| Validated pain score | None |
| Imaging outcome | None |
| Preclinical papers since 2015 | About 4, from one group |
A photo pair cannot fill those rows. Nothing in the published record lets anyone say what Cartalax does to a human joint.
Cartalax
The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.
Why people still report feeling better
Self-reports are not lies. They are just not controlled measurements.
Joint pain moves on its own. It flares and it settles. People usually start a new compound when they feel worst, so the next weeks often look like improvement no matter what was in the vial.
- Timing. Symptoms tend to drift back toward average after a bad stretch.
- Stacking. Most users change training, sleep or supplements at the same time.
- Expectation. Injections carry a strong expectation effect, which is why trials are blinded.
- Selection. People who felt nothing rarely post a photo set.
None of that tells you Cartalax failed. It tells you the question has not been asked properly yet. Zero Western RCTs means nobody has separated the peptide from the circumstances around it.
What you can actually verify before you buy
The biology is unverifiable right now. The vial is not.
A PubMed search for "Cartalax" or "Ala-Glu-Asp peptide" from 2015 forward returns a short list, around 4 papers, and you can run it yourself in under a minute. That is the honest starting point.
- Identity and purity. Ask for mass spec and HPLC on the specific lot. How to read a certificate of analysis shows what a real one contains.
- Handling. Short peptides are sensitive to heat and light. See peptide storage temperature.
- Legal status. These are research compounds, not approved drugs. Are peptides legal covers the framing.
A clean certificate proves the powder is what the label says. It proves nothing about what the powder does.
Cartalax
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- No published human study of Cartalax exists, so there is no measured before and after.
- The record is about 4 preclinical papers since 2015, all from one research group.
- The cell work used nanomolar concentrations and read gene expression, not patient outcomes.
- Most benefit claims borrow Epitalon data, which is a different, four-amino-acid peptide.
- Osteoarthritis affects 595 million people, and trials in that field use blinding and validated scores. Cartalax has neither.
- You can verify the vial with a certificate of analysis. You cannot verify the claim.
What we're watching
Any Cartalax before-and-after you find online is self-reported. No published study has photographed, scanned or scored a single person taking it.
Frequently asked questions
Are there any Cartalax before and after photos from a study?
No. There is no published human study of Cartalax, so there are no study photographs, no imaging and no pain scores. Every image online is user-submitted and uncontrolled.
How long does Cartalax take to work?
Nobody knows. No human trial has measured a time course, an onset or a duration for this peptide. Any timeline you read is someone's personal report, not a measured result.
Is Cartalax the same as Epitalon?
No. Cartalax is the AED tripeptide, about 333 Da. Epitalon is the AEDG tetrapeptide. Reviews like Araj and colleagues, 2025, are about Epitalon and do not test Cartalax.
Has Cartalax been tested for arthritis or joint pain?
Not in people. Osteoarthritis affects 595 million people worldwide per the GBD 2021 analysis, and the field uses blinded trials with validated scores. Cartalax has zero such trials.
What does the cell research actually show?
Ashapkin and colleagues, Molecular Biology Reports 2020, reported that short Khavinson peptides at nanomolar concentrations shifted expression of a small set of genes in aging human stem cell cultures. That is a dish result, not a clinical one.
What people actually report
These are self-reports, not evidence. No control group, no blinding, and no independent check that the vial held what the label claimed. They are collected here because people asking about Cartalax deserve an answer rather than a refusal, and because what the community believes is itself worth knowing. Quotes are excerpts; each links to the original post.
Uncontrolled, unverified self-report. Users take Cartalax for knee, hip and back pain, almost always stacked with BPC-157, TB-500, KPV, GHK-Cu or HGH, so nothing reported can be attributed to it alone. Most describe subcutaneous injection, though the earliest account here used oral capsules and swore off them. Reported amounts run from 500 mcg to 10 mg a day. Where relief is reported it is described as slow and partial, arriving in the second or third week. Dissent is common. Several ran it for months and reported nothing, and one poster ran a full kit alongside six other compounds, reported no improvement, and went on to a hip replacement.
Where the community and the published record disagree. The self-reports here describe injecting 500 mcg to 10 mg a day. The cartilage study the compound rests on is Myakisheva, Linkova, Polyakova and Ryzhak, Vrach 2023, 34(10):46-49, doi 10.29296/25877305-2023-10-08. It is rat chondrocytes in a dish, grown out of the intervertebral discs of 3-month-old and 20-month-old rats, so it is not a joint and not a person. It tested the AED tripeptide at 20, 200 and 2000 ng/mL. It reported 200 ng/mL as the minimum effective concentration, and it found that 200 and 2000 ng/mL produced the same stimulating effect. That matters, because the community's one troubleshooting move when 2 mg does nothing is to go to 5 mg and then 10 mg. The source experiment gives that no support: ten times more peptide did not do more in the dish, it did the same. A concentration in a culture well also cannot be converted into a daily injected amount, so none of the reported protocols trace back to this study at all.
“Still never touching those oral capsules again.”
“I took 2mg a day for 3 months and didn't notice any difference at all.”
“Joint pain seems to be down considerably but I can’t say for sure if it’s placebo or legit”
“I tried 2mg of cartalax for months and it absolutely nothing.”
Has anybody heard of Cartalax or the "Deadpool Blend" (Cartalax, bpc-157, and tb-500)?
“I’m not certain that my last batch wasn’t just glucose powder.”
“kinda goated niche pep (I think) really does work well though IMO”
Posts are quoted under fair use and linked to their authors. Nothing on this page is hosted here, and no claim above has been verified beyond confirming that the person wrote it.
References
- Ashapkin, V., Khavinson, V., Shilovsky, G., Linkova, N., & Vanyushin, B. (2020). Gene expression in human mesenchymal stem cell aging cultures: Modulation by short peptides. Molecular Biology Reports, 47(6), 4323–4329. https://doi.org/10.1007/s11033-020-05506-3
- Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 26(6), 2691. https://doi.org/10.3390/ijms26062691
- Khavinson, V., Diomede, F., Mironova, E., et al. (2020). AEDG peptide (epitalon) stimulates gene expression and protein synthesis during neurogenesis: Possible epigenetic mechanism. Molecules, 25(3), 609. https://doi.org/10.3390/molecules25030609
- GBD 2021 Osteoarthritis Collaborators. (2023). Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet Rheumatology, 5(9), e508–e522. https://doi.org/10.1016/S2665-9913(23)00163-7
- PubMed search: “AED tripeptide” OR “Cartalax” OR “Ala-Glu-Asp peptide”, 2015–2026. pubmed.ncbi.nlm.nih.gov PMID ?term=AED+tripeptide+Khavinson